Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications
Sanofi

Sanofi and Korean firm Hanmi have agreed to collaborate to develop a portfolio of experimental, long-acting diabetes treatments.

Under the terms of the agreement, Hanmi will receive an upfront payment of $435m and is eligible to receive up to $3.8bn in additional payments if key milestones are met in the development, registration and sales of the drugs.

Sanofi will obtain an exclusive worldwide license to develop and commercialise three treatments: efpeglenatide, a late-stage long-acting glucagon-like peptide-1, a fixed-dose weekly GLP-1RA/insulin drug combination.

Collectively, these therapeutic offerings are known as the 'Quantum Project' utilising Hanmi's proprietary Long Acting Protein / Peptide Discovery Platform called Lapscovery which prolongs the duration of action of biologics and extends a protein's half-life from weekly to monthly.

The companies state that the objective is to reduce the frequency and dosage of treatments for patients, which could potentially lower adverse events and optimise efficacy.

Pascale Witz, executive VP at Sanofi, said: “The agreement to develop these three investigational diabetes medicines confirms Sanofi's long-term commitment to people with this disease.

“We now have the opportunity to expand our existing portfolio by including medicines that are administered weekly as well as daily, which could extend our reach in basal insulin and expand our GLP-1-RA and GLP-RA/insulin combination prospects. In these ways, we aim to complement our current offering and work to serve a broader patient population.”

Hanmi will retain exclusive rights to co-commercialise these treatments in Korea and China as well as double-digit royalties on net sales, while Sanofi will obtain an exclusive worldwide license to develop and commercialise the three medications of the 'Quantum Project'.      

Sanofi this week also forged a $1.5bn deal with German biotech firm BioNTech to develop up to five cancer therapies.  

Article by
Nikhil Patel

5th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics